THE EFFECTIVENESS OF HIGH FLOW NASAL CANNULE OXYGENATION THERAPY (HFNC) ON CHANGES IN OXYGEN SATURATION IN COVID-19 WAS CONFIRMED IN PATIENTS IN COVID-19 ICU AT DUSTIRA HOSPITAL LEVEL II IN CIMAHI

Abstract

COVID-19 is a unique variant of the Coronavirus Disease-19 virus. As of July 31, 2021, the world had verified 197,943,446 cases of COVID-19 and 4,222,934 associated causes of death, while Indonesia had confirmed 3,409,658 cases and 94,119 associated causes of death. COVID-19 symptoms can be classed as mild, moderate, or severe. Experts recommend the use of HFNC and NIV as a first-aid measure in patients with respiratory failure. HFNC is a nasal cannula that distributes 60 liters per minute of warm, moist air. The purpose of this study was to assess the oxygen saturation values of individuals with confirmed Covid 19 before and during treatment with a High Flow Nasal Cannula. The inquiry was conducted using a pre-experimental one-group pretest-posttest design. The study was done by measuring oxygen saturation before delivering HFNC therapy, followed by administering HFNC therapy and watching individuals for one hour. The sample size was twelve respondents. We used the paired-test parametric test to analyze univariate and bivariate data (dependent t-test). The average oxygen saturation value prior to and during HFNC treatment was 87.25 and HFNC administration was 91.33. The 0.000 p-values derived from bivariate data analysis revealed that HFNC oxygenation treatment is effective at increasing oxygen saturation. Hospitals should be able to extend health services and facilities in the critical care unit, notably additional HFNC devices to decrease the likelihood of patients being intubated.